Pembrolizumab Shows Activity in Select Rare Sarcomas Pembrolizumab Shows Activity in Select Rare Sarcomas
The checkpoint inhibitor prolonged progression-free survival in patients with four subtypes of metastatic or unresectable locally advanced sarcomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Science Saturday: Regenerating muscles after cancer surgery
Advancements in microsurgery are making it possible to harness the body's healing power to regenerate muscle strength after some cancer surgeries, particularly surgery to remove soft tissue sarcoma. Mayo Clinic orthopedic oncologists are teaming with plastic surgeons in a procedure they've coined "oncoregeneration." They are seeking to perfect this procedure in which large muscle is transferred to close [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 19, 2020 Category: Databases & Libraries Source Type: news

Few High-Grade Soft Tissue Sarcoma Patients Receive Chemo
THURSDAY, Sept. 10, 2020 -- The rates of adults with high-grade soft tissue sarcoma (STS) who receive chemotherapy may be lower than expected, indicating a need for more aggressive systemic treatments, according to a study published in the August... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2020 Category: Pharmaceuticals Source Type: news

Insights into treating rare cancer tumours benefit patients
What is the best way to tackle sarcomas? Although clinical trials help to generate insight, they are hard to set up for rare diseases. An EU-funded project has organised several trials focusing on these malignancies, providing insight that is already helping to save more lives. It has also paved the way for further research to help patients. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - September 7, 2020 Category: Research Source Type: news

Chemotherapy is used to treat less than 25% of people with localized sarcoma
FINDINGSUCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.The researchers found that even among patients with the largest and most aggressive tumors, less than half (45%) received chemotherapy. The team also found that patients were more likely to be treated with chemotherapy at facilities that perform at least 55 surgeries for sarcom...
Source: UCLA Newsroom: Health Sciences - August 6, 2020 Category: Universities & Medical Training Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Dana-Farber study advances understanding of rare sarcoma
In this study, scientists discover how abnormal protein disrupts gene expression in synovial sarcoma. For the first time, scientists discover the molecular basis for the cancer-specific targeting properties of the culprit fusion protein found in synovial sarcoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

Stand Up To Cancer awards $1.1 million in grants to research teams
(Stand Up To Cancer) Stand Up To Cancer announced today five new awards that will cut across institutional and national lines to foster collaborative research and explore new paths to improve cancer treatment. The projects will receive a combined total of $1.1 million in funding to address some of the most pressing questions associated with colorectal, Ewing sarcoma, pancreatic, lung and pediatric cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 29, 2020 Category: International Medicine & Public Health Source Type: news

A mouse model was used to determine the personalized treatment for a cancer patient
(IDIBELL-Bellvitge Biomedical Research Institute) A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2020 Category: Cancer & Oncology Source Type: news

Finding hints at novel target for Ewing sarcoma therapy
(University of Texas Health Science Center at San Antonio) A genetic code-reading machine that is overactive in the pediatric cancer Ewing sarcoma causes cell structures called nucleoli to break up, researchers found. A team at UT Health San Antonio's Greehey Children's Cancer Research Institute will study how to take advantage of this finding therapeutically. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2020 Category: International Medicine & Public Health Source Type: news

Tazemetostat Shows Promise for Pleural Mesothelioma
Five different research groups at the American Society of Clinical Oncology annual meeting last month made presentations on the effectiveness of tazemetostat, a novel protein inhibitor, in fighting various cancers. Pleural mesothelioma was one of those cancers in which clear efficacy was demonstrated, raising hopes again for a future second-line therapy option. “It wasn’t the breakthrough you may be looking for, but there is a set of patients now that can benefit from this treatment for a period of time,” Dr. Marianna Koczywas, medical oncologist at City of Hope cancer treatment and research center in Cal...
Source: Asbestos and Mesothelioma News - June 24, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers have found a molecular explanation to a longstanding enigma in viral oncology
(University of Helsinki) The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi's Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2020 Category: Cancer & Oncology Source Type: news

Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
(University of Texas M. D. Anderson Cancer Center) The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Pomalidomide for Kaposi Sarcoma FDA Approves Pomalidomide for Kaposi Sarcoma
Pomalidomide is the first new treatment option for Kaposi sarcoma in more than 20 years; the drug is already marketed for multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Pomalidomide for Patients with AIDS-Related Kaposi Sarcoma
Pomalidomide was approved for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration Approves Bristol Myers Squibb ’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma
PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news

E-scooter  - a new source of danger in tumor endoprosthetics - den Toom DA, Bockholt S, Gosheger G, Budny T, Deventer N, Lübben T, Schneider KN.
A  24-year-old male patient who suffered a periprosthetic fracture of the left distal femur due to an e‑scooter accident was referred to the outpatient department of tumor orthopedics. The patient had been diagnosed with Ewing's sarcoma of the left prox... (Source: SafetyLit)
Source: SafetyLit - March 25, 2020 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Incidence and risk factors for suicide death among Kaposi's sarcoma patients: a surveillance, epidemiology, and end results analysis - Shen J, Zhu M, Li S, Wang Q, Wu J, Li Y, Wang Q, Bian X, Yang L, Jiang X, Xie J, Lu Y, Wang K, Li L.
BACKGROUND The suicide risk of patients with cancer is higher than the general population. Our research aimed to explore the Surveillance, Epidemiology, and End Results (SEER) database to define incidence and quest risk factors for death of suicide in pati... (Source: SafetyLit)
Source: SafetyLit - March 12, 2020 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Sarcoma Surveillance: A Review of Evidence and Guidelines Sarcoma Surveillance: A Review of Evidence and Guidelines
When it comes to surveillance strategies for sarcoma, what do existing guidelines and evidence recommend?Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 19, 2020 Category: Orthopaedics Tags: Orthopaedics Journal Article Source Type: news

Uganda: Ministry of Health Moves to Regulate Cancer Homes as Residents Turn Into Beggars
[Independent (Kampala)] Kampala -Agnes Emujong battles Kaposi's sarcoma, a type of cancer that usually affects people living with HIV. The disease has made her develop large protruding tumors on the nose and eye areas that have almost shrunk her face. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 19, 2020 Category: African Health Source Type: news

Mother could give birth to her own GRANDCHILD
Jasmine Bowley, 21, from Norwich, had her ovaries and Fallopian tubes removed when she developed pelvic Ewing's sarcoma aged seven - which also affected her womb. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2020 Category: Consumer Health News Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed five-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.“Shortening the radiation therapy from five weeks to five days has been a very meaningful change for patients,” said lead author Dr. Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. “Five weeks of daily treatments is a burdensome com mitment for patients. The daily back-and-forth can be expensive and time consuming, and it can really inte...
Source: UCLA Newsroom: Health Sciences - February 13, 2020 Category: Universities & Medical Training Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
(University of California - Los Angeles Health Sciences) A new study led by researchers at UCLA found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

UN Health Agency Predicts 80 Percent Rise in Cancer Burden Among Poorest Countries
Many specialist doctors and nurses in Africa are migrating to greener pastures, leaving cancer patients with few options. Credit: Jeffrey Moyo/IPSBy External SourceLONDON, Feb 7 2020 (IPS) Low- and middle-income countries could see an 80 per cent rise in cancer over the next 20 years if treatment and prevention services are not stepped up, according to the latest World Cancer Report. The report, compiled by the World Health Organization (WHO), warns that cancer prevention is taking a back seat in poor countries, as their health systems tackle such immediate problems as infectious diseases, child health and nutrition. The r...
Source: IPS Inter Press Service - Health - February 7, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Poverty & SDGs Source Type: news

St. Jude's scientist receives ACGT grant for sarcoma gene therapy
(Alliance for Cancer Gene Therapy) Stephen Gottschalk, MD, of St. Jude Children's Research Hospital receives $500k grant to use genetically engineered immune cells to attack pediatric sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2020 Category: Cancer & Oncology Source Type: news

Drug Trials Snapshots: TAZVERIK
TAZVERIK is a drug used to treat a type of cancer called advanced epithelioid sarcoma. It is to be used in patients 16 years and older when cancer has spread and cannot be completely removed by surgery. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Entrepreneur Leila Janah died from complications of epithelioid sarcoma. Here's what that is
Leila Janah, a fierce entrepreneur who worked to help those living below the poverty line, died in January from complications of epithelioid sarcoma -- a form of cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - February 2, 2020 Category: Consumer Health News Source Type: news

Treatment Combination May Be Effective for Antitumor Activity in Advanced Sarcoma
The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial. (Source: CancerNetwork)
Source: CancerNetwork - January 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Title: Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid SarcomaCategory: Health NewsCreated: 1/24/2020 12:00:00 AMLast Editorial Review: 1/27/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 27, 2020 Category: Cancer & Oncology Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Approval marks the first for a drug to treat this rare soft tissue sarcoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 25, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
FRIDAY, Jan. 24, 2020 -- Tazverik (tazemetostat) has received the first approval for treatment of adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that cannot be resected, the U.S. Food and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 24, 2020 Category: General Medicine Source Type: news

FDA approves tazemetostat for advanced epithelioid sarcoma
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Tazemetostat, First Drug for Rare Sarcoma FDA Approves Tazemetostat, First Drug for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first treatment option specifically for patients with epithelioid sarcoma
Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ). (Source: World Pharma News)
Source: World Pharma News - January 24, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Tazemetostat for the Treatment of Epithelioid Sarcoma
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2020 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 23, 2020 Category: Drugs & Pharmacology Source Type: news

B cells: New allies in sarcoma immunotherapy?
(INSERM (Institut national de la sant é et de la recherche m é dicale)) How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer? An international team led by Wolf Herv é Fridman with researchers from Inserm, Sorbonne Universit é and Universit é de Paris, has shown that B cells also play a major role in predicting of patient's response to immunotherapy. Their findings, to be published in Nature, pave the way for the personalization of treatments for patients with soft tissue sarcomas. (Source: EurekAlert! ...
Source: EurekAlert! - Medicine and Health - January 15, 2020 Category: International Medicine & Public Health Source Type: news

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news

Public Insurance Tied to Lower Cancer Survival in Young Patients
FRIDAY, Dec. 27, 2019 -- Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 15 in Cancer Medicine. Neela L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news

Teenager with incurable cancer refuses to stop smiling despite spending Christmas in hospital
Joseph Lunn, from Mitcham, south London, was diagnosed with synovial sarcoma, a rare and incurable cancer in his abdomen. He had four tumours removed over Christmas. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2019 Category: Consumer Health News Source Type: news

Combination of chemo and diabetes drugs shows potential for treating Ewing sarcoma
(Houston Methodist) Houston Methodist researchers propose a combination of two well-known drugs as a new treatment option for Ewing sarcoma -- one of them typically used to treat diabetes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2019 Category: Cancer & Oncology Source Type: news

SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing Sarcoma
The drug is currently the subject of an ongoing phase I/II clinical study for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Medtech in a Minute: 3M Quits Drug-Delivery, New FDA Commissioner, and More
It's Official, Hahn Will Lead FDA The U.S. Senate voted 72-18 to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news has been well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association. Hahn is a radiation oncologist who specializes in treating lung cancer and sarcoma.   3M Calls It Quits on Drug Delivery The company plans to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for $650 million plus a 17% noncontrolling interest...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

It & #039;s Official, Hahn Will Lead FDA
FDA officially has a new boss. The U.S. Senate voted 72-18 on Thursday to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news was largely well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association. “Dr. Hahn is an excellent choice to lead FDA, and we congratulate him on his swift and overwhelming bipartisan confirmation," said AdvaMed CEO Scott Whitaker. "During the confirmation process, Dr. Hahn demonstrated his deep understanding of the agency’s mission to pr...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news